T Cell Nouveau

12/07/2024

γδT Cell Project Adopted as Research and Development Support Program for Growth-Type Small and Medium Sized Enterprises (GO-TECH)
https://www.tcellnouveau.com/en/post/γδt-cell-project-adopted-as-research-and-development-support-program-for-growth-type-small-and-mediu

08/07/2024

https://www.tcellnouveau.com/en/post/amed-adopted-gd2-gitrl-car-project-as-strengthening-program-for-the-pharmaceutical-startup-ecosystem

One of our programs, GD2 GITRL CAR project, was adopted as Strengthening Program for the Pharmaceutical Startup Ecosystem Initiative 2024 by Japan Agency for Medical Research and Development (AMED) on June 14, and it was on the web on the same day (https://www.amed.go.jp/koubo/19/02/1902C_00047.html...

15/04/2024

https://www.tcellnouveau.com/en/post/election-of-executives-on-the-third-annual-2023fy-general-shareholder-meeting

We would like to inform you that the following officers were elected at our company's third annual (2023FY) general shareholder meeting and assumed their positions as follows. Along with Kazuto Takesako, Masanobu Kimura was nominated and approved as representative director to strengthen the manageme...

12/01/2024

January 13, 2024 T Celll Nouveau Inc. Notice of Patent License Agreement for a Novel CAR T-Cell Therapy Targeting GD2 Antigen T Cell Nouveau Inc. (Headquartered in Chuo-ku, Tokyo and represented by Chairman and Representative Director, Kazuto Takesako, hereinafter referred to as the “Company”) h...

20/12/2023

https://lnkd.in/gATgByzv

24/04/2023

08/03/2023

We updated added Scientific Advisory Board page to our web site!

ティーセルヌーヴォー株式会社は臨床段階のバイオメディカル企業であり、三重大学 珠玖研究室が開発した最先端のTCR like CAR-T細胞療法を用いて、免疫系を賦活化することにより固形がんを治療することを目指しています。...

02/03/2023

https://www.tcellnouveau.com/en/post/announcement-on-changes-in-the-executive-team

Announcement on changes in the Executive team. The following nominations of Executive Officers were approved at the 2nd Ordinary General Shareholders Meeting held on February 28, 2023: Kazuto Takesako, Chairman and CEO Kiyoshi Inoguchi, President and COO Kei Fujioka, Director (external) Yoshiyuki Wa...

26/02/2023

https://www.tcellnouveau.com/en/post/license-agreement-for-novel-car-t-cell-therapy-targeting-prame-cancer-antigen

February 21, 2023 T Celll Nouveau Inc. Announcement of a license agreement for novel CAR-T cell therapy targeting PRAME cancer antigen. T Cell Nouveau Inc. (Headquartered in Tokyo and represented by CEO, Kiyoshi Inoguchi, hereinafter "the Company") concluded a license agreement with Mie University (...

26/02/2023

https://www.tcellnouveau.com/en/post/coverage-in-nikkei-biotech

ティーセルヌーヴォー、固形がんなどにT細胞受容体様のCAR-T療法を開発中：日経バイオテクONLINE (nikkeibp.co.jp)